Skip to main content

Table 2 SIR of ESKD in Japan compared with the total incidence of ESKD in Australia

From: Age- and gender-specific incidence rates of renal replacement therapy in Japan: an international comparison

Age group (years)

Males

Females

Incidence (95 % CI)a

Expected cases

SIR (95 % CI)

Incidence (95 % CI)a

Expected cases

SIR (95 % CI)

0–4

0.8 (0.5–1.1)

114

0.38 (0.27–0.51)

0.3 (0.2–0.6)

41

0.91 (0.64–1.24)

5–9

0.8 (0.5–1.1)

121

0.22 (0.14–0.32)

0.6 (0.41.0)

86

0.21 (0.12–0.33)

10–14

0.5 (0.3–0.8)

77

0.53 (0.38–0.72)

0.8 (0.5–1.1)

117

0.33 (0.23–0.45)

15–19

1.6 (1.3–2.1)

268

0.48 (0.40–0.57)

1.3 (1.0–1.7)

207

0.39 (0.31–0.49)

20–24

2.7 (2.2–3.3)

506

0.70 (0.63–0.78)

1.8 (1.4–2.3)

319

0.56 (0.49–0.65)

25–29

4.0 (3.4–4.7)

834

0.82 (0.76–0.88)

3.0 (2.5–3.6)

602

0.67 (0.61–0.74)

30–34

4.8 (4.1–5.6)

1152

1.20 (1.14–1.27)

4.0 (3.4–4.7)

933

0.78 (0.72–0.84)

35–39

7.4 (6.5–8.3)

1635

1.33 (1.28–1.39)

5.0 (4.3–5.7)

1080

0.97 (0.91–1.03)

40–44

10.4 (9.4–11.5)

2065

1.47 (1.42–1.52)

6.8 (6.0–7.7)

1327

1.09 (1.04–1.15)

45–49

13.7 (12.5–15.0)

2644

1.79 (1.74–1.84)

8.7 (7.9–9.8)

1666

1.34 (1.29–1.40)

50–54

18.5 (17.0–20.1)

4078

2.05 (2.00–2.09)

10.8 (9.7–12.0)

2393

1.66 (1.60–1.71)

55–59

23.6 (21.9–25.5)

5839

2.22 (2.18–2.26)

16.3 (14.8–17.8)

4122

1.37 (1.33–1.41)

60–64

32.1 (29.8–34.7)

6538

2.14 (2.10–2.18)

21.2 (19.4–23.3)

4567

1.45 (1.41–1.48)

65–69

49.8 (46.4–53.4)

8895

1.80 (1.77–1.83)

33.7 (31.1–36.6)

6616

1.24 (1.22–1.27)

70–74

80.6 (75.8–85.8)

12,225

1.45 (1.43–4.70)

50.1 (46.6–53.9)

8982

1.04 (1.02–1.06)

75–79

127.5 (120.6–134.9)

14,272

1.07 (1.05–1.09)

75.8 (71.1–80.8)

11,345

0.87 (0.85–0.89)

80–84

216.1 (204.7–228.1)

13,356

0.68 (0.67–0.70)

117.5 (110.8–124.7)

12,872

0.59 (0.58–0.60)

≥85

447.3 (524.7–570.0)

18,168

0.25 (0.24–0.26)

318.7 (305.3–332.8)

33,654

0.14 (0.14–0.15)

Total

26.1 (22.5–30.0)

92,784

1.19 (1.18–1.20)

17.0 (14.9–19.2)

90,930

0.68 (0.68–0.69)

  1. Reproduced from [3]
  2. CI confidence interval, ESKD end-stage kidney disease, SIR standardised incidence ratio
  3. aPer 100,000 population